Diseases, Conditions, Syndromes

Universal gut microbiome-derived signature predicts cirrhosis

Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease worldwide, affecting an estimated one-quarter of the global population. It is a progressive condition that, in worst cases, can lead to ...

Diseases, Conditions, Syndromes

Hospitalizations for chronic liver disease on the rise

(HealthDay)—Hospitalizations for chronic liver disease (CLD) increased from 2012 to 2016, reaching a total estimated national cost of $81.1 billion, according to a study published online April 2 in JAMA Network Open.

Diseases, Conditions, Syndromes

Nonalcoholic steatohepatitis will pose clinical, economic burden

Nonalcoholic steatohepatitis (NASH) is expected to pose a significant clinical and economic burden during the next 20 years for U.S. patients with type 2 diabetes mellitus (T2DM), according to a study published online Jan. ...

Medications

New treatment option for nonalcoholic fatty liver disease

A team led by Michael Trauner at MedUni Vienna's Division of Gastroenterology and Hepatology demonstrated the beneficial effect of synthetically produced bile acid with the active agent nor-ursodeoxycholic acid (nor-urso) ...

page 5 from 9